69 related articles for article (PubMed ID: 3129983)
1. Evaluation of risk factors in intraoperative bleeding tendency.
Halonen P; Linko K; Wirtavuori K; Hästbacka J; Ikkala E
Ann Chir Gynaecol; 1987; 76(6):298-302. PubMed ID: 3129983
[TBL] [Abstract][Full Text] [Related]
2. The significance of evaluating conventional inflammatory markers in Von Willebrand factor measurement.
Lippi G; Franchini M; Targher G; Poli G; Guidi GC
Clin Chim Acta; 2007 Jun; 381(2):167-70. PubMed ID: 17433810
[TBL] [Abstract][Full Text] [Related]
3. Non-steroidal anti-inflammatory drugs and gastrointestinal bleeding.
Lanas A
Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S37-42. PubMed ID: 10379468
[TBL] [Abstract][Full Text] [Related]
4. Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis.
Favaloro EJ; Soltani S; McDonald J; Grezchnik E; Easton L; Favaloro JW
Am J Clin Pathol; 2005 Dec; 124(6):910-7. PubMed ID: 16416741
[TBL] [Abstract][Full Text] [Related]
5. Definition of the bleeding tendency in factor XI-deficient kindreds--a clinical and laboratory study.
Bolton-Maggs PH; Patterson DA; Wensley RT; Tuddenham EG
Thromb Haemost; 1995 Feb; 73(2):194-202. PubMed ID: 7792729
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
[TBL] [Abstract][Full Text] [Related]
7. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
8. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
9. Defining patients at risk of non-steroidal anti-inflammatory drug gastropathy.
Russell RI
Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S14-8. PubMed ID: 10379464
[TBL] [Abstract][Full Text] [Related]
10. Bleeding time and concentrations of von Willebrand factor in patients with acute upper gastrointestinal bleeding.
Henriksson AE; Nilsson TK; Bergavist D
Eur J Surg; 1996 Aug; 162(8):627-31. PubMed ID: 8891620
[TBL] [Abstract][Full Text] [Related]
11. Interactions between anti-ulcer drugs and non-steroidal anti-inflammatory drugs in cirrhotic patients with bleeding esophagogastric varices.
Yoshida H; Mamada Y; Taniai N; Mineta S; Kawano Y; Mizuguchi Y; Kakinuma D; Kanda T; Tajiri T
Hepatogastroenterology; 2009; 56(94-95):1366-70. PubMed ID: 19950793
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of primary haemostasis in people with neurofibromatosis type 1.
Favaloro EJ; Zafer M; Nair SC; Hertzberg M; North K
Clin Lab Haematol; 2004 Oct; 26(5):341-5. PubMed ID: 15485464
[TBL] [Abstract][Full Text] [Related]
13. The hemostatic profiles of patients with Type O and non-O blood after acute normovolemic hemodilution with 6% hydroxyethyl starch (130/0.4).
Kang JG; Ahn HJ; Kim GS; Hahm TS; Lee JJ; Gwak MS; Choi SJ
Anesth Analg; 2006 Dec; 103(6):1543-8. PubMed ID: 17122237
[TBL] [Abstract][Full Text] [Related]
14. Thrombin-generating capacity in patients with von Willebrand's disease.
Rugeri L; Beguin S; Hemker C; Bordet JC; Fleury R; Chatard B; Negrier C; Dargaud Y
Haematologica; 2007 Dec; 92(12):1639-46. PubMed ID: 18055987
[TBL] [Abstract][Full Text] [Related]
15. Haemostasis with cryoprecipitate in patients undergoing surgery for severe von Willebrand disease.
Mathews V; Srivastava A; Nair SC; Chandy M
Natl Med J India; 2000; 13(4):188-90. PubMed ID: 11002685
[TBL] [Abstract][Full Text] [Related]
16. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study.
Nørgård B; Pedersen L; Johnsen SP; Tarone RE; McLaughlin JK; Friis S; Sørensen HT
Aliment Pharmacol Ther; 2004 Apr; 19(7):817-25. PubMed ID: 15043523
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
[TBL] [Abstract][Full Text] [Related]
18. Variations in the risk of gastrointestinal hemorrhage with non-steroidal anti-inflammatory drugs and localization of lesions.
Pulanić R; Dubravcić D; Ostojić-Pulanić B; Vrhovac B
Acta Med Croatica; 1998; 52(2):91-8. PubMed ID: 9682495
[TBL] [Abstract][Full Text] [Related]
19. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
20. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma.
Tsibouris P; Hendrickse MT; Isaacs PE
Aliment Pharmacol Ther; 2004 Sep; 20(6):645-55. PubMed ID: 15352913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
